Short answer
Eledon Pharmaceuticals, Inc. (ELDN) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Eledon Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 13, 2026
- Exhibit 99.1 contains the substantive financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- FDA alignment supports global Phase 3 kidney-transplant trial, targeting approximately 600 patients and initiation in late 2026
- BESTOW data showed eGFR approximately 12 mL/min/1.73 m² higher at 18 months versus tacrolimus, with p<0.05
- Islet-transplant study achieved insulin independence in all 12 patients, with mean latest HbA1c approximately 5.4%
- Cash, equivalents and short-term investments declined to $88.8M from $133.3M, funding operations into Q2 2027
- Q2 net loss widened to $31.6M, including a $9.6M non-cash warrant-liability loss; operating loss was $22.9M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eledon Pharmaceuticals, Inc. 8-K filings
Get the next ELDN 8-K as it lands
Follow ELDN for push alerts, or ask the research agent what this filing means.